Loading clinical trials...

Transcorneal Electrical Stimulation Therapy for Retinal Disease | Clinical Trials | Clareo Health

COMPLETEDNA

Transcorneal Electrical Stimulation Therapy for Retinal Disease

Transcorneal Electrical Stimulation Therapy for Retinal Disease - A Randomized, Single-blind Pilot Study

NCT00804102•Okuvision GmbH

Summary

Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Retinitis pigmentosa, Macula off, Primary open angle Glaucoma, Hereditary Macular Degeneration, Treated Retina detachment, Retinal Artery Occlusion, Retinal Vein Occlusion, Non-Arthritic-Anterior-Ischemic Optic-Neuropathy, Hereditary autosomal dominant Optic atrophy, dry Age-related Macular Degeneration, Ischemic Macula edema

Exclusion Criteria

•Severe other disease such as non-proliferative diabetic retinopathy, exudative Age-related Macular Degeneration
•Age above 99 years

Key Dates

Start Date

January 1, 2008

Primary Completion Date

April 1, 2011

Completion Date

April 1, 2011

Last Updated

May 4, 2012

Enrollment

ACTUAL participants

Conditions

Retinitis PigmentosaMacula OffPrimary Open Angle GlaucomaHereditary Macular DegenerationTreated Retina DetachmentRetinal Artery OcclusionRetinal Vein OcclusionNon-Arthritic-Anterior-Ischemic Optic-NeuropathyHereditary Autosomal Dominant Optic AtrophyDry Age Related Macular DegenerationIschemic Macula Edema

Interventions

Transcorneal Electrical Stimulation

DEVICE

DTL-electrode attached without energy

DEVICE

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

NCT05926583

Retinitis Pigmentosa

View study

RECRUITINGPHASE2

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT07174726

X-Linked Retinitis Pigmentosa (XLRP)

View study

RECRUITINGNA

Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 4, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Transcorneal Electrical Stimulation Therapy for Retinal Disease

Inclusion Criteria

Exclusion Criteria

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital

DSLT for Reducing Medication in Glaucoma

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population